Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- New Proposals by Regulatory Reform Council Include Elimination of 14-Day Prescription Limit
November 29, 2013
- New Combination Drugs Containing Non-Innovative APIs Should Be Priced Based on Prices of Other APIs Contained: CSIMC Subcommittee
November 29, 2013
- CSIMC Bill Payer Rep Repeats Opposition to Replacing Special Price Cut for Off-Patent Drugs with New Rule
November 28, 2013
- Ministry Revises Plan to Set First Generic Prices, Suggests 50% or 60%
November 28, 2013
- MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
- RMPs Required for Generics when RMPs Submitted for Original Products: Health Ministry
November 27, 2013
- Nearly 60% of Face-to-Face Consultations from July 2011 through September 2013 Involved Drugs: PMDA
November 26, 2013
- Subcommittee Agrees to Introduction of New Price Reduction Rule for Long-Listed Drugs Next Year; Will Continue to Discuss Details
November 22, 2013
- JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
- Upper House Passes Amended Pharmaceutical Affairs Law and Law to Ensure Safety of Regenerative Medicine
November 21, 2013
- Decision on Long-Term Prescriptions to Be Based on Results of Discussions at CSIMC: Government
November 21, 2013
- Plan Floated to Merge NIBIO Unit, JST to Create Japan-Version NIH: Govt Source
November 20, 2013
- Finance Minister Pushes Drastic Price Cuts for Off-Patent Drugs with Low Generic Penetration
November 20, 2013
- Administrative Reform Council Calls for Further Promotion of Generics, Elimination of OTC-like Drugs from Insurance Coverage
November 20, 2013
- PAFSC’s Second Committee Supports Approval of NBI’s Lung Cancer Drug, Takeda’s Malignant Lymphoma Treatment
November 19, 2013
- PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29
November 19, 2013
- 1st Anticancer Drugs OK’ed for External Reviews under New Advanced Healthcare Scheme
November 18, 2013
- Subcommittee Agrees On Plan to Include Rate of Generic Drug Use in Determining Functional Evaluation Coefficient II for DPC Hospitals
November 18, 2013
- Reimbursement Listing of OBLEAN Put on Hold, Faces Rare CSIMC Setback
November 15, 2013
- MHLW Proposes Special Price Reductions for Long-Listed Drugs with Less than 60% of Generic Substitution After 5 Years
November 15, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…